Evidence map›Paper›PMID 42729701›Full record

ArticleMaterials today. Bio2026

Engineering tolerogenic mRNA-LNPs for allergen-specific immune reprogramming in pollen allergy.

Zhiying Yao, Dingyou Wang, Yuhan Zhang, Peilin Xin, Yutong Li, Elif Naz Cerav, Di Tang, Zhirui Zhao, Zhili Wang, Huiyang Wang and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zhiying YaoSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Dingyou WangDepartment of Allergy, The Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian, 116021, China.
Yuhan ZhangSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Peilin XinDepartment of Allergy, The Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian, 116021, China.
Yutong LiSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Elif Naz CeravSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Di TangSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Zhirui ZhaoSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Zhili WangSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Huiyang WangSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Huizi LiuSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Zhihui LiangSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Changying XueSchool of Bioengineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.
Han XiaoCollege of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, 310058, China.
Gang ChengSchool of Engineering, Westlake University, Hangzhou, 310024, China.
Xiubo FanDepartment of Clinical Translational Research, Singapore General Hospital, Singapore.
Shan DengDepartment of Allergy, The Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian, 116021, China.
Tian XiaMarina Biotherapeutics, Inc., 371 Mingxing Road, Hangzhou, 311215, China.
Bingbing SunSchool of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, Dalian, 116024, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pollen allergy is a prevalent respiratory allergic disease, yet current allergen immunotherapy (AIT) remains limited by safety concerns and insufficient induction of durable immune tolerance. Here, we develop an engineered mRNA-LNP platform for allergen-specific tolerance induction by integrating allergen and delivery system optimization. A non-secretory mRNA encoding the major mugwort pollen allergen Art v 1 fused with invariant chain (mArt v 1) was designed to reduce IgE-mediated activation while promoting tolerogenic allergen processing. This antigen was delivered using a mannose-functionalized LNP formulation (mAr-C18

Indexed as

Immune toleranceLipid nanoparticlesmRNA vaccinePollen allergyRegulatory T cell

Identifiers

PMID42729701
PMCPMC13562674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.